SCHEMBL3638744

SCHEMBL3638744

CCOc1ccc(/C=N/O)c(OC)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 4/20 0.50
TSHR P16473 2/20 0.50
GRIN2D O15399 2/20 0.49
GRIN3B O60391 2/20 0.49
GRIN1 Q05586 2/20 0.49
GRIN2A Q12879 2/20 0.49
GRIN2B Q13224 2/20 0.49
GRIN2C Q14957 2/20 0.49
GRIN3A Q8TCU5 2/20 0.49
CYP1A1 P04798 2/20 0.48
CYP1B1 Q16678 2/20 0.48
LMNA P02545 2/20 0.48
HTT P42858 1/20 0.48
POLB P06746 1/20 0.46
CYP1A2 P05177 3/20 0.46
ALDH1A1 P00352 4/20 0.44
GAA P10253 2/20 0.44
AMY1A P0DUB6 1/20 0.44
KDM4E B2RXH2 1/20 0.44
ERN1 O75460 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3638747 1.00 HPGD (0.50) HPGDTSHRGRIN2DGRIN3BGRIN1
SCHEMBL16508880 0.86 CYP1A1 (0.47) HPGDGRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL30481109 0.85 GRIN2D (0.64) HPGDTSHRGRIN2DGRIN3BGRIN1
SCHEMBL2009040 0.85 GRIN2D (0.64) HPGDTSHRGRIN2DGRIN3BGRIN1
SCHEMBL2009041 0.85 GRIN2D (0.64) HPGDTSHRGRIN2DGRIN3BGRIN1
SCHEMBL8237102 0.85 GRIN2D (0.64) HPGDTSHRGRIN2DGRIN3BGRIN1
SCHEMBL20151704 0.79 HPGD (0.48) HPGDTSHRLMNAHTTPOLB
SCHEMBL20148167 0.79 HPGD (0.48) HPGDTSHRLMNAHTTPOLB
SCHEMBL702232 0.79 ALDH1A1 (0.71) TSHRCYP1A1CYP1B1LMNACYP1A2
SCHEMBL28347627 0.79 CYP1A1 (0.50) HPGDTSHRCYP1A1CYP1B1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2155751-A1 PYRROLOPYRIMIDIN-7-ONE DERIVATIVES AND THEIR USE AS PHARMACEUTICALS AstraZeneca AB (SE) 2010-02-24 EP disclosed
US-20090099195-A1 Therapeutic Compounds 570 ASTRAZENECA AB (SE) 2009-04-16 US disclosed
WO-2008136756-A1 PYRROLOPYRIMIDIN-7-ONE DERIVATIVES AND THEIR USE AS PHARMACEUTICALS ASTRAZENECA AB (SE) 2008-11-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090099195-A1 Therapeutic Compounds 570 OPRL1, OPRK1, OPRM1 HPGD 1347/4885TSHR 1066/4885GRIN2D 1590/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.